Takehiro Shiinoki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Takehiro Shiinoki has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
Koya Fujimoto
Department of Radiation Oncology, Graduate School of Medicine, Yamaguchi University, Ube, Japan
18 shared publicationsYuki Yuasa
Department of Radiological Technology Yamaguchi University Hospital Ube Yamaguchi Japan
18 shared publicationsHidekazu Tanaka
Department of Radiation Oncology Graduate School of Medicine Yamaguchi University Ube Yamaguchi Japan
10 shared publications- Fumitake Fujii
Department of Mechanical Engineering, Yamaguchi University, Yamaguchi, Japan
7 shared publications Yusuke Kawazoe
Department of Radiological Technology, Yamaguchi University Hospital, Ube, JAPAN
7 shared publications- Hidekazu Tanaka
Department of Radiation Oncology, Yamaguchi University Graduate School of Medicine, Ube, Japan
6 shared publications
Latest Publications
- Open Access
- 27 July 2026
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 27 (8)
Estimation of pulmonary function from time‐resolved dynamic chest radiography using machine learning in patients with respiratory disease
Background: Pulmonary function tests (PFTs), particularly spirometry, are the reference standard for assessing airflow limitation in respiratory diseases such as chronic obstructive pulmonary disease (COPD) and interstitial pulmonary disease. However, spirometry requires substantial patient cooperation and may be unreliable in children, the elderly, and patients with cognitive impairment, and its use was further limited during the COVID‐19 pandemic. Dynamic chest radiography (DCR), which captures sequential thoracic images during respiration at low radiation dose, has emerged as a promising modality for evaluating respiratory dynamics, but its potential to quantitatively estimate pulmonary function through radiomic analysis remains insufficiently explored. Purpose: This study aimed to determine the potential of radiomic features of the lung on DCR to predict pulmonary function (FEV 1 , forced expiratory volume in the first second; FVC, forced vital capacity) and to classify patients at high risk (FEV 1 /FVC). Methods: We retrospectively analysed data from 151 patients. The DCRs at end‐inspiration (EI), end‐expiration (EE), and the respiratory phase of maximum variation in the lung area from EI to EE (insp2exp vmax ) or from EE to EI (exp2insp vmax ) were defined based on the lung area. A respiratory motion map was also calculated. To combine the defined DCR and respiratory motion map, feature extraction was performed, followed by the least absolute shrinkage and selection operator (LASSO). Predictive regression and classification models with various radiomic feature combinations (nos. 1–6) were constructed for pulmonary function. Pearson's correlation coefficients (R) were calculated for FEV 1 and FVC, and the area under the curve (AUC) was calculated for FEV 1 /FVC. Our predictive models were compared using the conventional formula. Results: We constructed a predictive regression and classification model for FEV 1 , FVC, and FEV 1 /FVC ratio using DCR images and a respiratory motion map. The model accuracy with DCR at each respiratory phase and the respiratory motion map‐based radiomic features was better than that of the conventional method. Conclusions: In this single‐center retrospective study, radiomic features extracted from DCR at multiple respiratory phases combined with respiratory motion maps showed promise for estimating pulmonary function, outperforming conventional demographic‐based prediction. External validation in multi‐center cohorts is warranted before clinical translation.
- 27 July 2026
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 27 (8)
Open AccessEstimation of pulmonary function from time‐resolved dynamic chest radiography using machine learning in patients with respiratory disease
Background: Pulmonary function tests (PFTs), particularly spirometry, are the reference standard for assessing airflow limitation in respiratory diseases such as chronic obstructive pulmonary disease (COPD) and interstitial pulmonary disease. However, spirometry requires substantial patient cooperation and may be unreliable in children, the elderly, and patients with cognitive impairment, and its use was further limited during the COVID‐19 pandemic. Dynamic chest radiography (DCR), which captures sequential thoracic images during respiration at low radiation dose, has emerged as a promising modality for evaluating respiratory dynamics, but its potential to quantitatively estimate pulmonary function through radiomic analysis remains insufficiently explored. Purpose: This study aimed to determine the potential of radiomic features of the lung on DCR to predict pulmonary function (FEV 1 , forced expiratory volume in the first second; FVC, forced vital capacity) and to classify patients at high risk (FEV 1 /FVC). Methods: We retrospectively analysed data from 151 patients. The DCRs at end‐inspiration (EI), end‐expiration (EE), and the respiratory phase of maximum variation in the lung area from EI to EE (insp2exp vmax ) or from EE to EI (exp2insp vmax ) were defined based on the lung area. A respiratory motion map was also calculated. To combine the defined DCR and respiratory motion map, feature extraction was performed, followed by the least absolute shrinkage and selection operator (LASSO). Predictive regression and classification models with various radiomic feature combinations (nos. 1–6) were constructed for pulmonary function. Pearson's correlation coefficients (R) were calculated for FEV 1 and FVC, and the area under the curve (AUC) was calculated for FEV 1 /FVC. Our predictive models were compared using the conventional formula. Results: We constructed a predictive regression and classification model for FEV 1 , FVC, and FEV 1 /FVC ratio using DCR images and a respiratory motion map. The model accuracy with DCR at each respiratory phase and the respiratory motion map‐based radiomic features was better than that of the conventional method. Conclusions: In this single‐center retrospective study, radiomic features extracted from DCR at multiple respiratory phases combined with respiratory motion maps showed promise for estimating pulmonary function, outperforming conventional demographic‐based prediction. External validation in multi‐center cohorts is warranted before clinical translation.
- Open Access
- 2 November 2025
- Published by MDPI AG in Bioengineering
- Vol. 12 (11) , 1197
Marker-Less Lung Tumor Tracking from Real-Time Color X-Ray Fluoroscopic Images Using Cross-Patient Deep Learning Model
Fiducial marker implantation for tumor localization in radiotherapy is effective but invasive and carries complication risks. To address this, we propose a marker-less tumor tracking framework to explore the feasibility of a cross-patient deep learning model, aiming to eliminate the need for per-patient retraining. A novel degradation model generates realistic simulated data from digitally reconstructed radiographs (DRRs) to train a Restormer network, which transforms clinical fluoroscopic images into clean, DRR-like images. Subsequently, a DUCK-Net model, trained on DRRs, performs tumor segmentation. We conducted a feasibility study using a clinical dataset from 7 lung cancer patients, comprising 100 distinct treatment fields. The framework achieved an average processing time of 179.8 ms per image and demonstrated high accuracy: the median 3D Euclidean tumor center tracking error was mm, with directional errors of mm (LR), mm (SI), and mm (AP). These promising results validate our approach as a proof-of-concept for a cross-patient marker-less tumor tracking solution, though further large-scale validation is required to confirm broad clinical applicability.- 2 November 2025
- Published by MDPI AG in Bioengineering
- Vol. 12 (11) , 1197
Open AccessMarker-Less Lung Tumor Tracking from Real-Time Color X-Ray Fluoroscopic Images Using Cross-Patient Deep Learning Model
Fiducial marker implantation for tumor localization in radiotherapy is effective but invasive and carries complication risks. To address this, we propose a marker-less tumor tracking framework to explore the feasibility of a cross-patient deep learning model, aiming to eliminate the need for per-patient retraining. A novel degradation model generates realistic simulated data from digitally reconstructed radiographs (DRRs) to train a Restormer network, which transforms clinical fluoroscopic images into clean, DRR-like images. Subsequently, a DUCK-Net model, trained on DRRs, performs tumor segmentation. We conducted a feasibility study using a clinical dataset from 7 lung cancer patients, comprising 100 distinct treatment fields. The framework achieved an average processing time of 179.8 ms per image and demonstrated high accuracy: the median 3D Euclidean tumor center tracking error was mm, with directional errors of mm (LR), mm (SI), and mm (AP). These promising results validate our approach as a proof-of-concept for a cross-patient marker-less tumor tracking solution, though further large-scale validation is required to confirm broad clinical applicability. - 13 May 2025
- Published by Springer Nature in Physical and Engineering Sciences in Medicine
- Vol. 48 (2) , 915-926
Biomechanics-driven dose stress metrics for radiation-induced acute xerostomia prediction among head and neck radiation therapy
Xerostomia is a condition commonly affecting patients subjected to radiation therapy (RT) for head and neck cancer (HNC) treatment. We propose dose metrics that consider the stress of parotid glands (PGs) during RT by using finite element analysis (FEA) of structural changes captured via computed tomography (CT) images acquired before and during RT to evaluate their effectiveness in predicting acute xerostomia. Thirty patients treated for HNC via in volumetric modulated arc therapy were enrolled. Patient complaints were considered by radiation oncologists based on the common terminology criteria for adverse events and scored as xerostomia grade 0 (XG-0), XG-1, or XG-2. All patients underwent CT both before and during RT (CTini and CTbst, respectively). FE-based deformable image registration was performed from the CTini images to the CTbst images, following which the stress of PGs was calculated and generate the dose–stress histograms (DSH). Four classical indices (volume change, mean dose, CT value change in PGs, and weight change), the mean stress, dose–volume histogram (DVH), and DSH metrics were used to evaluate the effectiveness of our approach. No significant differences among patients w/wo acute xerostomia groups were noted based on the four classical indices, mean stress, or DVH metrics; however, DSH metrics presented significant differences (p < 0.05) and demonstrated good predictive performance in distinguishing patients w/wo acute xerostomia (AUC > 0.70). The proposed metrics can analyze stress values without additional examinations and demonstrate significant differences between groups w/wo acute xerostomia and between different XGs.
- 13 May 2025
- Published by Springer Nature in Physical and Engineering Sciences in Medicine
- Vol. 48 (2) , 915-926
Biomechanics-driven dose stress metrics for radiation-induced acute xerostomia prediction among head and neck radiation therapy
Xerostomia is a condition commonly affecting patients subjected to radiation therapy (RT) for head and neck cancer (HNC) treatment. We propose dose metrics that consider the stress of parotid glands (PGs) during RT by using finite element analysis (FEA) of structural changes captured via computed tomography (CT) images acquired before and during RT to evaluate their effectiveness in predicting acute xerostomia. Thirty patients treated for HNC via in volumetric modulated arc therapy were enrolled. Patient complaints were considered by radiation oncologists based on the common terminology criteria for adverse events and scored as xerostomia grade 0 (XG-0), XG-1, or XG-2. All patients underwent CT both before and during RT (CTini and CTbst, respectively). FE-based deformable image registration was performed from the CTini images to the CTbst images, following which the stress of PGs was calculated and generate the dose–stress histograms (DSH). Four classical indices (volume change, mean dose, CT value change in PGs, and weight change), the mean stress, dose–volume histogram (DVH), and DSH metrics were used to evaluate the effectiveness of our approach. No significant differences among patients w/wo acute xerostomia groups were noted based on the four classical indices, mean stress, or DVH metrics; however, DSH metrics presented significant differences (p < 0.05) and demonstrated good predictive performance in distinguishing patients w/wo acute xerostomia (AUC > 0.70). The proposed metrics can analyze stress values without additional examinations and demonstrate significant differences between groups w/wo acute xerostomia and between different XGs.
- 29 April 2025
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 69 (4) , 524-530
A Comparative Study of Radical Radiotherapy in Very Elderly and Non‐Very Elderly Patients With Malignant Tumour Using Pairwise Matching
Introduction: This study aimed to compare the outcomes and complications following radical radiotherapy between very elderly patients aged ≥ 90 years and non‐very elderly patients using pairwise matching analysis.Methods: Data of patients who underwent radical radiotherapy at our hospital between January 2013 and March 2024 and those who were aged ≥ 90 years at the start of radical radiotherapy were extracted. Data of control patients were extracted by pairwise matching from patients aged < 90 years who underwent radical radiotherapy during the same period. Pairwise matching was performed using the following criteria: (i) cancer type, (ii) TNM classification, (iii) histological type, (iv) concurrent chemotherapy, (v) prescribed biological effective dose, (vi) performance status, (vii) sex and (viii) ability to walk. The local control (LC), cancer‐specific survival (CSS) and overall survival (OS) rates were calculated from the date of completion of radiotherapy.Results: Forty patients from each group were analysed. There were no significant differences in LC, CSS or OS rates between the two groups. The completion rate of radiotherapy and the incidence rate of adverse events were not significantly different between the two groups.Conclusion: In this study, there was no difference in the outcomes of radiotherapy between very elderly and non‐very elderly patients. Our findings may aid clinicians in the treatment of nonagenarian patients.
- 29 April 2025
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 69 (4) , 524-530
A Comparative Study of Radical Radiotherapy in Very Elderly and Non‐Very Elderly Patients With Malignant Tumour Using Pairwise Matching
Introduction: This study aimed to compare the outcomes and complications following radical radiotherapy between very elderly patients aged ≥ 90 years and non‐very elderly patients using pairwise matching analysis.Methods: Data of patients who underwent radical radiotherapy at our hospital between January 2013 and March 2024 and those who were aged ≥ 90 years at the start of radical radiotherapy were extracted. Data of control patients were extracted by pairwise matching from patients aged < 90 years who underwent radical radiotherapy during the same period. Pairwise matching was performed using the following criteria: (i) cancer type, (ii) TNM classification, (iii) histological type, (iv) concurrent chemotherapy, (v) prescribed biological effective dose, (vi) performance status, (vii) sex and (viii) ability to walk. The local control (LC), cancer‐specific survival (CSS) and overall survival (OS) rates were calculated from the date of completion of radiotherapy.Results: Forty patients from each group were analysed. There were no significant differences in LC, CSS or OS rates between the two groups. The completion rate of radiotherapy and the incidence rate of adverse events were not significantly different between the two groups.Conclusion: In this study, there was no difference in the outcomes of radiotherapy between very elderly and non‐very elderly patients. Our findings may aid clinicians in the treatment of nonagenarian patients.
- Open Access
- 18 March 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Access
- Vol. 12, 40809-40826
Markerless Lung Tumor Localization From Intraoperative Stereo Color Fluoroscopic Images for Radiotherapy
Accurately determining tumor regions from stereo fluoroscopic images during radiotherapy is a challenging task. As a result, high-density fiducial markers are implanted around tumors in clinical practice as internal surrogates of the tumor, which leads to associated surgical risks. This study was conducted to achieve lung tumor localization without the use of fiducial markers. We propose training a cascade U-net system to perform color to grayscale conversion, enhancement, bone suppression, and tumor detection to determine the precise tumor region. We generated Digitally Reconstructed Radiographs (DRRs) and tumor labels from 4D planning CT images as training data. An improved maximum projection algorithm and a novel color-to-gray conversion algorithm were proposed to improve the quality of the generated training data. Training a bone suppression model using bone-enhanced and bone-suppressed DRRs enables the bone suppression model to achieve better bone suppression performance. The mean peak signal-to-noise ratios in the test sets of the trained translation and bone suppression models are 39.284 ± 0.034 dB and 37.713 ± 0.724 dB, respectively. The results indicate that our proposed markerless tumor localization method is applicable in seven out of ten cases; in applicable cases, the centroid position error of the tumor detection model is less than 1.13 mm; and the calculated tumor center motion trajectories using the proposed network highly coincide with the motion trajectories of implanted fiducial markers in over 60% of captured groups, providing a promising direction for markerless tumor localization tracking methods.
- 18 March 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Access
- Vol. 12, 40809-40826
Open AccessMarkerless Lung Tumor Localization From Intraoperative Stereo Color Fluoroscopic Images for Radiotherapy
Accurately determining tumor regions from stereo fluoroscopic images during radiotherapy is a challenging task. As a result, high-density fiducial markers are implanted around tumors in clinical practice as internal surrogates of the tumor, which leads to associated surgical risks. This study was conducted to achieve lung tumor localization without the use of fiducial markers. We propose training a cascade U-net system to perform color to grayscale conversion, enhancement, bone suppression, and tumor detection to determine the precise tumor region. We generated Digitally Reconstructed Radiographs (DRRs) and tumor labels from 4D planning CT images as training data. An improved maximum projection algorithm and a novel color-to-gray conversion algorithm were proposed to improve the quality of the generated training data. Training a bone suppression model using bone-enhanced and bone-suppressed DRRs enables the bone suppression model to achieve better bone suppression performance. The mean peak signal-to-noise ratios in the test sets of the trained translation and bone suppression models are 39.284 ± 0.034 dB and 37.713 ± 0.724 dB, respectively. The results indicate that our proposed markerless tumor localization method is applicable in seven out of ten cases; in applicable cases, the centroid position error of the tumor detection model is less than 1.13 mm; and the calculated tumor center motion trajectories using the proposed network highly coincide with the motion trajectories of implanted fiducial markers in over 60% of captured groups, providing a promising direction for markerless tumor localization tracking methods.
- 29 February 2024
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 69 (5) , 055033
Biomechanical imaging biomarker during chemoradiotherapy predicts treatment response in head and neck squamous cell carcinoma
Objective . For response-adapted adaptive radiotherapy (R-ART), promising biomarkers are needed to predict post-radiotherapy (post-RT) responses using routine clinical information obtained during RT. In this study, a patient-specific biomechanical model (BM) of the head and neck squamous cell carcinoma (HNSCC) was proposed using the pre-RT maximum standardized uptake value (SUV max ) of 18 F-fluorodeoxyglucose (FDG) and tumor structural changes during RT as evaluated using computed tomography (CT). In addition, we evaluated the predictive performance of BM-driven imaging biomarkers for the treatment response of patients with HNSCC who underwent concurrent chemoradiotherapy (CCRT). Approach . Patients with histologically confirmed HNSCC treated with definitive CCRT were enrolled in this study. All patients underwent CT two times as follows: before the start of RT (pre-RT) and 3 weeks after the start of RT (mid-RT). Among these patients, 67 patients who underwent positron emission tomography/CT during the pre-RT period were included in the final analysis. The locoregional control (LC), progression-free survival (PFS), and overall survival (OS) prediction performances of whole tumor stress change (TS) between pre- and mid-RT computed using BM were assessed using univariate, multivariate, and Kaplan–Meier survival curve analyses, respectively. Furthermore, performance was compared with the pre and post-RT SUV max , tumor volume reduction rate (TVRR) during RT, and other clinical prognostic factors. Main results . For both univariate, multivariate, and survival curve analyses, the significant prognostic factors were as follows ( p < 0.05): TS and TVRR for LC; TS and pre-RT FDG-SUV max for PFS; and TS only for OS. In addition, for 2 year LC, PFS, and OS prediction, TS showed a comparable predictive performance to post-RT FDG-SUV max . Significance . BM-driven TS is an effective prognostic factor for tumor treatment response after CCRT. The proposed method can be a feasible functional imaging biomarker that can be acquired during RT using only routine clinical data and may provide useful information for decision-making during R-ART.
- 29 February 2024
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 69 (5) , 055033
Biomechanical imaging biomarker during chemoradiotherapy predicts treatment response in head and neck squamous cell carcinoma
Objective . For response-adapted adaptive radiotherapy (R-ART), promising biomarkers are needed to predict post-radiotherapy (post-RT) responses using routine clinical information obtained during RT. In this study, a patient-specific biomechanical model (BM) of the head and neck squamous cell carcinoma (HNSCC) was proposed using the pre-RT maximum standardized uptake value (SUV max ) of 18 F-fluorodeoxyglucose (FDG) and tumor structural changes during RT as evaluated using computed tomography (CT). In addition, we evaluated the predictive performance of BM-driven imaging biomarkers for the treatment response of patients with HNSCC who underwent concurrent chemoradiotherapy (CCRT). Approach . Patients with histologically confirmed HNSCC treated with definitive CCRT were enrolled in this study. All patients underwent CT two times as follows: before the start of RT (pre-RT) and 3 weeks after the start of RT (mid-RT). Among these patients, 67 patients who underwent positron emission tomography/CT during the pre-RT period were included in the final analysis. The locoregional control (LC), progression-free survival (PFS), and overall survival (OS) prediction performances of whole tumor stress change (TS) between pre- and mid-RT computed using BM were assessed using univariate, multivariate, and Kaplan–Meier survival curve analyses, respectively. Furthermore, performance was compared with the pre and post-RT SUV max , tumor volume reduction rate (TVRR) during RT, and other clinical prognostic factors. Main results . For both univariate, multivariate, and survival curve analyses, the significant prognostic factors were as follows ( p < 0.05): TS and TVRR for LC; TS and pre-RT FDG-SUV max for PFS; and TS only for OS. In addition, for 2 year LC, PFS, and OS prediction, TS showed a comparable predictive performance to post-RT FDG-SUV max . Significance . BM-driven TS is an effective prognostic factor for tumor treatment response after CCRT. The proposed method can be a feasible functional imaging biomarker that can be acquired during RT using only routine clinical data and may provide useful information for decision-making during R-ART.
- Open Access
- 22 January 2024
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 25 (6) , e14280
Intra‐ and inter‐fractional variations of tumors with fiducial markers measured using respiratory‐correlated computed tomography images for respiratory gated lung stereotactic body radiation therapy
Purpose: This study evaluated the intra‐ and inter‐fractional variation of tumors with fiducial markers (FMs), relative to the tumor‐FM distance, to establish how close an FM should be inserted for respiratory‐gated stereotactic body radiation therapy (RG‐SBRT).Methods: Forty‐five lung tumors treated with RG‐SBRT were enrolled. End‐expiratory computed tomography (CT) (CTplan) and four‐dimensional‐CT (4D‐CT) scans were obtained for planning. End‐expiratory CT (CTfr) scanning was performed before each fraction. The FMs were divided into two groups based on the median tumor‐FM distance in the CTplan (Dp). For the intra‐fractional variation, the correlations between the corresponding tumor and FM intra‐fractional motions, defined as the centroid coordinates of those in each 0–90% phase, with the 50% phase of 4D‐CT as the origin, were calculated in the left‐right, anterior‐posterior, and superior‐inferior directions. Furthermore, the maximum difference in the tumor‐FM distance in each phase of 4D‐CT scan, based on those in the 50% phase of 4D‐CT scan (Dmax), was obtained. Inter‐fractional variation was defined as the maximum distance between the tumors in CTplan and CTfr, when the CT scans were fused based on each FM or vertebra.Results: The median Dp was 26.1 mm. While FM intra‐fractional motions were significantly and strongly correlated with the tumor intra‐fractional motions in only anterior‐posterior and superior‐inferior directions for the Dp > 26 mm group, they were significantly and strongly correlated in all directions for the Dp ≤ 26 mm group. In all directions, Dmax values of the Dp ≤ 26 mm group were lower than those of the Dp > 26 mm group. The inter‐fractional variations based on the Dp ≤ 26 mm were smaller than those on the Dp > 26 mm and on the vertebra in all directions.Conclusions: Regarding intra‐ and inter‐fractional variation, FMs for Dp ≤ 26 mm can increase the accuracy for RG‐SBRT.
- 22 January 2024
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 25 (6) , e14280
Open AccessIntra‐ and inter‐fractional variations of tumors with fiducial markers measured using respiratory‐correlated computed tomography images for respiratory gated lung stereotactic body radiation therapy
Purpose: This study evaluated the intra‐ and inter‐fractional variation of tumors with fiducial markers (FMs), relative to the tumor‐FM distance, to establish how close an FM should be inserted for respiratory‐gated stereotactic body radiation therapy (RG‐SBRT).Methods: Forty‐five lung tumors treated with RG‐SBRT were enrolled. End‐expiratory computed tomography (CT) (CTplan) and four‐dimensional‐CT (4D‐CT) scans were obtained for planning. End‐expiratory CT (CTfr) scanning was performed before each fraction. The FMs were divided into two groups based on the median tumor‐FM distance in the CTplan (Dp). For the intra‐fractional variation, the correlations between the corresponding tumor and FM intra‐fractional motions, defined as the centroid coordinates of those in each 0–90% phase, with the 50% phase of 4D‐CT as the origin, were calculated in the left‐right, anterior‐posterior, and superior‐inferior directions. Furthermore, the maximum difference in the tumor‐FM distance in each phase of 4D‐CT scan, based on those in the 50% phase of 4D‐CT scan (Dmax), was obtained. Inter‐fractional variation was defined as the maximum distance between the tumors in CTplan and CTfr, when the CT scans were fused based on each FM or vertebra.Results: The median Dp was 26.1 mm. While FM intra‐fractional motions were significantly and strongly correlated with the tumor intra‐fractional motions in only anterior‐posterior and superior‐inferior directions for the Dp > 26 mm group, they were significantly and strongly correlated in all directions for the Dp ≤ 26 mm group. In all directions, Dmax values of the Dp ≤ 26 mm group were lower than those of the Dp > 26 mm group. The inter‐fractional variations based on the Dp ≤ 26 mm were smaller than those on the Dp > 26 mm and on the vertebra in all directions.Conclusions: Regarding intra‐ and inter‐fractional variation, FMs for Dp ≤ 26 mm can increase the accuracy for RG‐SBRT.
- Open Access
- 25 December 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (1) , 25
Differences in Radiosensitivity According to EGFR Mutation Status in Non-Small Cell Lung Cancer: A Clinical and In Vitro Study
Unlike drug selection, radiation parameters (field, dose) are not based on driver gene mutations in patients with metastatic non-small cell lung cancer (NSCLC). This study aimed to compare radiosensitivity in NSCLC with and without EGFR driver gene mutations using clinical and in vitro data. The clinical study included 42 patients who underwent whole-brain radiotherapy for brain metastases from NSCLC; of these, 13 patients had EGFR mutation-positive tumors. The Kaplan–Meier method was used to calculate the cranial control rate without intracranial recurrence. In the in vitro study, colony formation and double-strand DNA breaks were examined in two EGFR mutation-negative and three EGFR mutation-positive NSCLC-derived cell lines. Colony formation was assessed 14 days after irradiation with 0 (control), 2, 4, or 8 Gy. DNA double-strand breaks were evaluated 0.5 and 24 h after irradiation. EGFR mutation-positive patients had a significantly better cranial control rates than EGFR mutation-negative patients (p = 0.021). EGFR mutation-positive cells formed significantly fewer colonies after irradiation with 2 or 4 Gy than EGFR mutation-negative cells (p = 0.002, respectively) and had significantly more DNA double-strand breaks at 24 h after irradiation (p < 0.001). Both clinical and in vitro data suggest that EGFR mutation-positive NSCLC is radiosensitive.
- 25 December 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (1) , 25
Open AccessDifferences in Radiosensitivity According to EGFR Mutation Status in Non-Small Cell Lung Cancer: A Clinical and In Vitro Study
Unlike drug selection, radiation parameters (field, dose) are not based on driver gene mutations in patients with metastatic non-small cell lung cancer (NSCLC). This study aimed to compare radiosensitivity in NSCLC with and without EGFR driver gene mutations using clinical and in vitro data. The clinical study included 42 patients who underwent whole-brain radiotherapy for brain metastases from NSCLC; of these, 13 patients had EGFR mutation-positive tumors. The Kaplan–Meier method was used to calculate the cranial control rate without intracranial recurrence. In the in vitro study, colony formation and double-strand DNA breaks were examined in two EGFR mutation-negative and three EGFR mutation-positive NSCLC-derived cell lines. Colony formation was assessed 14 days after irradiation with 0 (control), 2, 4, or 8 Gy. DNA double-strand breaks were evaluated 0.5 and 24 h after irradiation. EGFR mutation-positive patients had a significantly better cranial control rates than EGFR mutation-negative patients (p = 0.021). EGFR mutation-positive cells formed significantly fewer colonies after irradiation with 2 or 4 Gy than EGFR mutation-negative cells (p = 0.002, respectively) and had significantly more DNA double-strand breaks at 24 h after irradiation (p < 0.001). Both clinical and in vitro data suggest that EGFR mutation-positive NSCLC is radiosensitive.
- Open Access
Immune Checkpoint Inhibitors after Radiation Therapy Improve Overall Survival Rates in Patients with Stage IV Lung Cancer
This exploratory and retrospective study aimed to evaluate whether there is a difference in the overall survival (OS) rates of patients with stage IV lung cancer who underwent radiation therapy (RT) depending on the presence or absence of immune checkpoint inhibitors (ICIs) and the timing of their use. Eighty patients with histologically confirmed stage IV lung cancer were enrolled, and ICIs were administered to thirty (37.5%). ICIs were administered before RT and after RT in 11 and 20 patients, respectively. The median follow-up period was 6 (range: 1–37) months. Patients treated with ICIs had significantly better OS rates than those not treated with ICIs (p < 0.001). The 6-month OS rates in patients treated with and without ICIs were 76.3% and 34.5%, respectively. The group that received ICI therapy after RT had a significantly better OS rate than the group that received ICI therapy prior to RT (6-month OS: 94.7% vs. 40.0%, p < 0.001). In the multivariate analysis, performance status (0–1 vs. 2–4) and ICI use after RT were significant factors for OS (p = 0.032 and p < 0.001, respectively). Our results suggest that ICI administration after RT may prolong the OS of patients with stage IV lung cancer.
Open AccessImmune Checkpoint Inhibitors after Radiation Therapy Improve Overall Survival Rates in Patients with Stage IV Lung Cancer
This exploratory and retrospective study aimed to evaluate whether there is a difference in the overall survival (OS) rates of patients with stage IV lung cancer who underwent radiation therapy (RT) depending on the presence or absence of immune checkpoint inhibitors (ICIs) and the timing of their use. Eighty patients with histologically confirmed stage IV lung cancer were enrolled, and ICIs were administered to thirty (37.5%). ICIs were administered before RT and after RT in 11 and 20 patients, respectively. The median follow-up period was 6 (range: 1–37) months. Patients treated with ICIs had significantly better OS rates than those not treated with ICIs (p < 0.001). The 6-month OS rates in patients treated with and without ICIs were 76.3% and 34.5%, respectively. The group that received ICI therapy after RT had a significantly better OS rate than the group that received ICI therapy prior to RT (6-month OS: 94.7% vs. 40.0%, p < 0.001). In the multivariate analysis, performance status (0–1 vs. 2–4) and ICI use after RT were significant factors for OS (p = 0.032 and p < 0.001, respectively). Our results suggest that ICI administration after RT may prolong the OS of patients with stage IV lung cancer.